Sociedad Americana de Hirudoterapia

Egyptian Drug Authority

EDA · Egypt · middle east

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Egypt's Egyptian Drug Authority (formed 2019, replacing the older CAPA / Central Administration of Pharmaceutical Affairs) — leech therapy regulated as a medical device with parallel traditional-medicine context.

Regulatory Profile

Agency type
national regulator
Region
middle east
Country
Egypt
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Law No. 151 of 2019 — Establishment of the Egyptian Drug Authority
  • Ministerial Decree No. 296 of 2009 — Medical devices regulation
  • Pharmacy Practice Law No. 127 of 1955 (as amended)

Prescriber Requirements

  • Egyptian Medical Syndicate-registered MD prescription required
  • Nursing application under physician's order per Nursing Syndicate scope
  • Hijama (cupping) practitioners are licensed under separate Ministry of Health programme; leech therapy is not part of hijama scope but operates alongside it

Supply Chain & GMP

EDA Medical Device Registration; importer requires Egyptian Drug Authority licensing. Arabic-language labelling mandatory.

Import/Export Rules

Import via EDA approval + General Authority for Veterinary Services clearance. CITES via EEAA (Egyptian Environmental Affairs Agency).

Reimbursement Context

Universal Health Insurance System (rolling out 2018–2032) covers inpatient procedures under DRG-style bundling; outpatient hirudotherapy is private-pay.

ASH Editorial Notes

Egypt's traditional-medicine ecosystem (Tibb Nabawi / prophetic medicine) has cultural overlap with leech therapy via the hadith of al-Bukhari; legal practice remains regulated under modern biomedical pathways.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.